AUG 21, 2014 08:45 AM PDT

From Genetics to Genetic Medicine: Gene Therapy for vision restoration as a case study

Speakers
  • Assistant Professor, Harvard Medical School, Assistant Scientist, Schepens Eye Research Institute, Massachusetts Eye and Ear
    Biography
      Assistant Professor, Harvard Medical School
      <br />Assistant Scientist, Schepens Eye Research Institute, Massachusetts Eye and Ear
      <br />Director, Gene Transfer Vector Core (GTVC)
      <br />Associate Director, Ocular Genomics Institute (OGI)
      <br />Investigator, Berman-Gund Laboratory for Retinal Degenerations, Howe Laboratory
      <br />Affiliate Faculty, Harvard Stem Cell Institute
      <br />
      <br />Luk H. Vandenberghe, PhD, trained as a biochemical engineer through his training at the University in Leuven, Belgium where he later also obtained his doctoral degree in Medical Sciences. Most of his graduate and postdoctoral work was performed at the University of Pennsylvania in Philadelphia in the leading gene therapy laboratories of Carl June, James Wilson, and Jean Bennett. In 2012, Dr. Vandenberghe set up a lab at the Schepens Eye Research Institute and Mass Eye and Ear in Boston where he is Assistant Professor at Harvard Medical School. Currently he is Director of the Grousbeck Gene Therapy Center and Associate Director of the Ocular Genomics Institute, both primarily focused at bringing gene therapies for vision restoration to the clinic.
      <br />
      <br />In previous work Dr. Vandenberghe has co-discovered, developed, and characterized novel serotypes of the adeno-associated virus (including AAV8,9), several of which are now in wide use at preclinical and clinical experimental stages for a host of target tissues and indications. His work has elucidated key insights into the host response of AAV in humans in the context of pre-existing immunity of this virus endemic in humans. Dr. Vandenberghe is a co-founder of a biotechnology company called GenSight Biologics (Paris, France) and named inventor in over a dozen published and pending patents of gene therapy related technologies.
      <br />
      <br />The Vandenberghe lab at Harvard studies gene therapy approaches for neurosensory disorders with a focus on clinical programs for retinal dystrophies. Its broader ambition is to make gene therapy a widely applicable clinical modality in ophthalmology and beyond. Toward this goal his program builds innovative vector technologies to overcome current translational hurdles.&nbsp; His research brings together molecular virology and immunology, synthetic biology, engineering, and medicine in attempt to understand and improve the challenges of the therapeutic potential of in vivo gene transfer.
      <br />

    Abstract:

    Gene therapy for two forms of inherited retinal degeneration have met promising safety and efficacy endpoints in early stage clinical trials. These approaches made use of a replication defective virus or vector based on the adeno-associated virus type 2 (AAV2), a small non enveloped ssDNA virus endemic in human population. AAV2 targets the retinal pigment epithelium (RPE) at high efficiency in small and large animal models, which is the primary target in these studies. Retinal disease however has a range of etiologies and cell types at the basis of its pathogenesis, and a broader set of tools to deliver therapeutic genes to the retina is required. Here, we describe our past and current efforts to develop novel vectors and therapeutic strategies to unlock genetic treatment for retinal blinding disorders.


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    JUN 29, 2018 09:00 AM PDT
    C.E. CREDITS
    JUN 29, 2018 09:00 AM PDT
    DATE: June 29, 2018TIME: 09:00AM PDT, 12:00PM EDT There is significant epidemiological evidence to suggest that the consumption of a high-broccoli diet is associated with a r...
    Loading Comments...